Clinical Trial Results: Positive data from Arcturus Therapeutics' clinical trials for its mRNA vaccine candidates typically leads to stock price increases, while negative or inconclusive results can cause declines.

Regulatory Approvals: Approvals from regulatory agencies like the FDA for Arcturus' vaccines or therapies significantly boost investor confidence and drive the stock price up. Delays or rejections negatively impact the price.

Competition: Advances in mRNA technology and vaccine development by competitors like Moderna and BioNTech can put downward pressure on Arcturus' stock, especially if those companies gain market share or achieve better clinical outcomes.

Partnerships and Collaborations: Strategic partnerships with pharmaceutical companies or research institutions can be viewed positively, suggesting validation of Arcturus' technology and potential for future revenue. Termination of such partnerships can have the opposite effect.

Financial Performance: Revenue, earnings, and cash flow reported by Arcturus influence investor sentiment. Strong financial performance can increase investor confidence and stock price, while losses or cash burn can lead to decreases.

Overall Market Conditions: General economic trends and market sentiment, particularly regarding the biotechnology sector, can impact Arcturus' stock. A bullish market tends to lift most stocks, while a bearish market can pull them down.

News and Public Perception: News articles, social media discussions, and overall public opinion regarding mRNA vaccines and Arcturus specifically can influence investor behavior and stock price.

Manufacturing and Supply Chain: Issues related to manufacturing capacity, supply chain disruptions, or the ability to produce vaccines at scale can negatively affect the stock price.

Intellectual Property: The strength and breadth of Arcturus' patent portfolio are important. Loss of key patents or legal challenges can erode investor confidence.

Management Team: Changes in the management team or concerns about the company's leadership can influence investor sentiment and stock price.